Video

Dr. Bunn on Current Role of Precision Medicine for Lung Cancer

Paul A. Bunn, Jr, MD, professor of Medicine in Medical Oncology and head of the Division of Medical Oncology at the University of Colorado, discusses the current role of precision medicine in lung cancer.

Paul A. Bunn, Jr, MD, professor of Medicine in Medical Oncology, head of the Division of Medical Oncology at the University of Colorado, discusses the current role of precision medicine in lung cancer.

Bunn explains that there are several biomarkers that can predict which therapy is going to be most beneficial as a patient begins treatment. Since there are multiple molecular biomarkers, it is easier and more cost effective to execute them all at the same time by utilizing next-generation sequencing (NGS). It has now become standard for patients with adenocarcinoma to do NGS testing first.

Looking at PD-L1 expression by immunohistochemistry has also become an important, standard step prior to beginning treatment, he explains. Studies have shown that if more than 49% of tumor cells express PD-L1, pembrolizumab (Keytruda) can be a superior treatment to chemotherapy.

Related Videos
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.
Neal D. Shore, MD, FACS
Sheldon M. Feldman, MD
Louis Crain Garrot, MD
Michel Delforge, MD, PhD
Thach-Giao Truong, MD
Aparna Parikh, MD